GLP-1tirzepatidetype 2 diabetesbeta-cell functionsemaglutide

Systematic review finds tirzepatide raises beta-cell function indices in type 2 diabetes

Eight reports covering 3,442 participants showed HOMA2-B gains of 77% to 163%, but most evidence came from post hoc, industry-funded analyses.

By Maren Holt · Senior Reporter, GLP-1

Sep 21 20:00 ETSource: Cureus

The wire

01A PRISMA-guided systematic review in Cureus pooled eight reports across six populations; tirzepatide 5-15 mg weekly raised HOMA2-B 77% to 163% and lifted the clamp disposition index roughly six-fold.
02Intact proinsulin fell up to 55% and the proinsulin/C-peptide ratio up to 49%, exceeding placebo, dulaglutide and semaglutide 1 mg, suggesting reduced secretory demand on beta cells.
03Heterogeneity prevented meta-analysis, risk of bias was high or serious in three reports, no study assessed function after drug withdrawal, and the review was unfunded and unregistered.

From the source

Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review
Cureus · 2026 Sep · Mahmoud R, Zarrouq Yousif AA, Osman AFM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42923463/